JLL Partners Inc., a 26-year-old private-equity firm based in New York, boosted the cash it has returned to fund investors since the start of last year to $1.7 billion by completing two deals this week, according to William Miles, the head of investor relations.

JLL garnered $731 million when drug producer Patheon Inc. wrapped up a merger yesterday with vitamin maker Royal DSM NV’s drug business, generating about a 200 percent gain on its equity investment, Miles said in a telephone interview. On March 10, the firm recouped almost half its $85 million investment in BioClinica Inc. when the clinical researcher was recapitalized and merged with a competitor.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.